Prosecution Insights
Last updated: November 04, 2026
Application No. 17/933,352

MESENCHYMAL STEM CELL-DERIVED EXTRACELLULAR VESICLES AND USES THEREOF FOR TREATING AND DIAGNOSING FIBROTIC DISEASES

Non-Final OA §101§112
Filed
Sep 19, 2022
Priority
Jun 06, 2019 — provisional 62/858,154 +3 more
Examiner
KAPUSHOC, STEPHEN THOMAS
Art Unit
1683
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Exopharma Inc.
OA Round
1 (Non-Final)
47%
Grant Probability
Moderate
1-2
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 47% of resolved cases
47%
Career Allowance Rate
347 granted / 744 resolved
-13.4% vs TC avg
Strong +54% interview lift
Without
With
+53.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 9m
Avg Prosecution
53 currently pending
Career history
822
Total Applications
across all art units

Statute-Specific Performance

§101
23.3%
-16.7% vs TC avg
§103
22.3%
-17.7% vs TC avg
§102
11.4%
-28.6% vs TC avg
§112
34.4%
-5.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 744 resolved cases

Office Action

§101 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority The instant application is a DIV of application 16/893,271 which resulted in US Patent 11,607,428. The claims of the instant application correspond to Group IV from the Restriction requirement of 05/18/2022 in the parent application, and as such the provisions of 35 USC 121 preclude a rejection over the patented claims. Election/Restrictions Applicants’ election with traverse of the particular species that are: The combination of miRNAs and WNT proteins as analytes in EVs; The particular miRNA combination that is: miR-192-5p; miR215-5p; miR-320c; and miR206; and The additional biomarker that is CCL18 in the reply filed on 07/29/2026 is acknowledged. The traversal is on the ground(s) that there is not a search burden in the search and examination of the different species of the claimed methods. . This is not found persuasive because a reference pertaining to one element (e.g.: a specific first miRNA species) would not be expected to be a reference pertaining to any other different elements (e.g.: a second specific miRNA species that is separate and distinct form the first miRNA species); as such there is a clear search burden in the search an examination of the claims as they encompass all of the different species. The requirement is still deemed proper and is therefore made FINAL. In light of the Examiners search and analysis of the elected species, the species election requirement of 05/29/2026 as it was applied between parts I(a) (miRNAs in the EVs) and I(c) (the combination of miRNAs and WNT proteins in the EVs); and the species election of part II (different additional biomarkers) are withdrawn. Claim Objections Claim 53 is objected to because of the following informalities: the claims recites a list of sample types as “a urine tissue or body fluid sample”, but the different elements in the list should be separated by commas as in “a urine, tissue, or body fluid sample”. Appropriate correction is required. Claim Rejections - 35 USC § 112 - Indefiniteness The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 53-65 and 97-103 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claims 53-65 and 97-103 are unclear over the inconsistent recitation of different sample types in the various steps of the claims as recited in claim 53. For example, steps a) and b) are directed to obtaining samples of, and isolating EVs from, any of “a urine tissue or body fluid sample”. But the measuring of miRNA expression, as recited in step c), is directed only to the urine sample. So it is unclear what steps are performed on tissue or body fluid sample is those are the source of the sample and EVs. Additionally, the identifying of step e) make us of miRNA and/or WNT protein levels that are specifically recited as “in the EVs from the tissue or body fluid sample”. But there is no requirement that miRNA are measured in EVs from tissue or from body fluids. Additionally the claims are unclear because there is no step that is directed to any measuring or WNT protein levels or the comparison of measured levels to control levels. It is unclear what steps are intended to be required by or encompassed by the claimed methods. Claims 53-65 and 97-103 are unclear over recitation of the phrase “identifying the patient”, as recited in step e) of claim 53 because there is no antecedent basis for any “patient”. Claim Rejection - Improper Markush Group Claims 54 is rejected on the basis that it contains an improper Markush grouping of alternatives. See In re Harnisch, 631 F.2d 716, 721-22 (CCPA 1980) and Ex parte Hozumi, 3 USPQ2d 1059, 1060 (Bd. Pat. App. & Int. 1984). A Markush grouping is proper if the alternatives defined by the Markush group (i.e., alternatives from which a selection is to be made in the context of a combination or process, or alternative chemical compounds as a whole) share a “single structural similarity” and a common use. A Markush grouping meets these requirements in two situations. First, a Markush grouping is ordinarily proper if all the members of the group belong to a recognized class (whether physical, chemical, or art recognized) and are disclosed in the specification to possess at least one property in common which is mainly responsible for their function in the claimed invention, and it is clear from their very nature or from the prior art that all members possess this property. Second, where a Markush grouping describes alternative chemical compounds, whether by words or chemical formulas, and the alternatives do not belong to a recognized class as set forth above, the members of the Markush grouping may be considered to share a “single structural similarity” and common use where the alternatives share both a substantial structural feature and a common use that flows from the substantial structural feature. See MPEP § 2117(II). The Markush grouping of: one or more of miR-134-5p, miR-196b-5p, miR-629-5p, miR-206, miR-192-5p, miR-320c, miR-125a-3p, miR-215-5p, miR-642a-3p, miR-576-3p, and miR-3679-5p As encompassed by claim 54 is improper because the alternatives defined by the Markush grouping do not share both a single structural similarity and a common use for the following reasons: It is first noted that MPEP 2117(II) states that “A Markush claim may be rejected under judicially approved “improper Markush grouping” principles when the claim contains an improper grouping of alternatively useable members. A Markush claim contains an “improper Markush grouping” if either: (1) the members of the Markush group do not share a “single structural similarity” or (2) the members do not share a common use. Supplementary Guidelines at 7166 (citing In re Harnisch, 631 F.2d 716, 721-22, 206 USPQ 300, 305 (CCPA 1980)). “Members of a Markush group share a “single structural similarity” when they belong to the same recognized physical or chemical class or to the same art-recognized class (prong 1) and the members of a Markush group share a common function or use when they are disclosed in the specification or known in the art to be functionally equivalent (prong 2). The phrase “significant structural element is shared by all of the alternatives” refers to cases where the compounds share a common chemical structure which occupies a large portion of their structures, or in case the compounds have in common only a small portion of their structures, the commonly shared structure constitutes a structurally distinctive portion in view of existing prior art, and the common structure is essential to the common property or activity. A recognized physical class, a recognized chemical class, or an art-recognized class is a class wherein “there is an expectation from the knowledge in the art that members of the class will behave in the same way in the context of the claimed invention. In other words, each member could be substituted one for the other, with the expectation that the same intended result would be achieved” (see MPEP 2117(II)). Here, the recited alternative species do not share a single structural similarity, as the different biomarkers (i.e.: each different miRNA) each have a different chemical structure in that each consist of a different nucleic acid sequence. The only structural similarity present is that all of different elements comprise nucleotides. The fact that the biomarkers comprise nucleotides does not per se support a conclusion that they have a common single structural similarity because the structural description of comprising nucleotides is not what is essential and mainly responsible for the asserted common activity of being associated with fibrosis. Accordingly, while the different biomarkers are asserted to have the property of being correlated with fibrosis, they do not share a substantial structural similarity essential to this activity. Further, there is no expectation from the knowledge in the prior art that miRNAs (generically), or the particular different elements of the Markush group (i.e.: the specific miRNAs), behave in the same manner and can be substituted for one another with the same intended result achieved. There is no evidence of record to establish that it is clear from their very nature that the recited biomarkers possess the common property of being correlated with fibrosis. For example, where the specification teaches that some particular miRNAs are upregulated in fibrosis, and some particular miRNAs are downregulated in fibrosis, the skilled artisan with the knowledge that members of the Markush group may not behave in the same way in the context of the claimed invention and could not necessarily be substituted one for the other, with the expectation that the same intended result would be achieved. Following this analysis, the claims are rejected as containing an improper Markush grouping. Claim Rejections - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Claims 53-65 and 97-103 are rejected under 35 U.S.C. 101 because the claimed invention is directed to abstract ideas and natural phenomena without significantly more. The claim(s) recite(s) identifying a patient as one that can benefit therapeutically from being treated for a fibrotic disease based on a determination (as consonant with the election ) that includes the detection of miRNA dysregulation. Where the claims are directed to determination of a presence of a treatable pathology based on a measure of miRNA levels, the claims include an abstract an abstract idea which is a mental process; the correlation of data and information to make a judgment or reach a conclusion which can be performed in the human mind (MPEP 2016.04(a)(2)(III). Such abstract ideas (i.e.: mental processes) are further embodied in steps of determining dysregulation of a biomarker by the comparison to a control. Additionally, where the claims are directed to the asserted association between miRNA dysregulation and the presence of a treatable fibrosis pathology, and such miRNAs and their relative levels are a natural part of the fibrosis pathology, the claims are directed to ta natural phenomenon (MPEP 2106.04(b)). This judicial exception is not integrated into a practical application because there are no practical steps performed as a result of any comparison of biomarker level or identification of a patient as treatable. The claims end with an identification based on a asserted association between dysregulation as determined by compared biomarker levels, and the presence of treatable pathology. The claim(s) does/do not include additional elements that are sufficient to amount to significantly more than the judicial exception because the claims recite only general steps related to the processing of samples to measure a biomarker (e.g.: miRNA level), but such methods were well understood, routine and conventional in the related art. Choi et al (2013) reviews the various transcriptomic and proteomic analyses of EVs showing that the prior art is replete with detection of miRNAs and proteins in EVs. Claim Rejections - 35 USC § 112 – Scope of Enablement The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 53-65 and 97-103 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for (as consonant with the election): A precision medicine method for identifying a human patient as one that can benefit therapeutically from being treated for pulmonary fibrosis, the method comprising: a) obtaining a urine sample from the subject and from a healthy control; b) isolating EVs from the urine sample obtained from the subject and healthy control; c) measuring a level of expression of each of miR-192-5p; miR215-5p; miR-320c; and miR206 in the EVs from the urine sample from the subject and in the EVs from the urine sample from the healthy control; d) determining that expression of the miR206 is decreased, and the expression levels of miR-192-5p, miR215-5p, and miR-320c are increased, in the EVs from the subject as compared to the levels in the in the EVs from the healthy control; and e) identifying the patient as one that can benefit therapeutically from being treated for a pulmonary fibrosis does not reasonably provide enablement for the methods as claimed which encompass any dysregulation (i.e.: increased or decreased compared to a control) of any miRNAs in EVs from any type of sample (i.e.: any tissue or body fluid) for the identification a need for treatment of any fibrotic disease (e.g.: lung, kidney, liver). The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims. Nature of the invention and the breadth of the claims The rejected claims are directed to methods of detecting the presence of fibrosis (i.e.: a subject that can benefit from being treated for a fibrotic disease). The claims, as consonant with the election, include the detection of dysregulation of miRNAs for the identification of the presence of fibrosis, and encompass the identification of fibrosis in any tissue (as generically encompassed by claim 53) or any of a variety of specific tissues (as recited in claim 64). The claims encompass the detection of any type of dysregulation of any miRNAs (e.g.: as generically encompassed by claim 53), or the detection of any type of dysregulation of any of a variety of specific miRNAs (e.g.: claim 54). The claims encompass the detection of expression levels in EVs from any type of tissue or body fluid sample. The claims thus require knowledge of an association between a wide variety of expression levels of any miRNAs from different sample with any fibrosis pathology. Direction provided by the specification and working example The instant specification (p.178) provides an example of the analysis of miRNA in EVs from subjects with idiopathic pulmonary fibrosis (IPF; fibrosis of lung tissue). Relevant to the breadth of the methods of the claims, the specification teaches the isolation of EVs from urine samples of subjects and healthy controls. The specification (Table 13 on p.180) teaches that EVs from subjects should specific dysregulation of eleven miRNAs: PNG media_image1.png 332 438 media_image1.png Greyscale The specification does not teach the analysis of EVs from non-urine samples, or the analysis of subject with fibrosis other than lung fibrosis. State of the art, level of skill in the art, and level of unpredictability While the state of the art and level of skill in the art with regard to the analysis of gene expression levels in any sample is high, the unpredictability in associating any expression levels of any miRNAs from any samples with a particular pathology, such as fibrosis, is higher. Such unpredictability is demonstrated by the related art. Because the claims require any dysregulation (increased or decreased) of any miRNAs for the detection of fibrosis, while only teaching a lung fibrosis example, it is relevant to point out the unpredictability if associating any particular expression level of any particular miRNA with any particular fibrosis pathology. For example, Vettori et al (2012) teaches a review of miRNAs associated with different fibrosis phenotypes, and demonstrates (Table 3) that different miRNAs may be anti- or pro-fibrotic, and related to fibrosis in different non-overlapping tissue types. Similarly, Chen et al (2017) provides an understanding of the state of the art with regard to associating particular miRNA expression levels in different tissues to particular pathologies. The reference provides that miR-615-5p is downregulated in pancreatic ductal adenocarcinoma and HCC (hepatocellular carcinoma) tissues, but upregulated in prostate cancer cells, concluding that miRNA expression, even in the same pathological phenotype, is dependent upon cellular context. Moreover, because the claimed methods generically encompass the examination of any samples from any subjects, it is relevant to point out the unpredictability in applying the particular results of the example of the specification to other subjects or sample types. Hoshikawa et al (2003) teaches unpredictability with regard to applying gene expression results among different organisms; the analysis of gene expression in lung tissue in response to hypoxic conditions which lead to pulmonary hypertension (Fig. 1) demonstrates that the gene expression profile in mouse is different from that observed in rat (Tables 1-4; p.209 - Abstract). And Similarly, Cobb et al (2002) teaches the analysis of gene expression in spleen and liver samples from septic mice; when compared to a non-septic sample, the relevant expression profiles of the septic mouse spleen and the septic mouse liver contain different nucleic acids at different levels (Table 1; p.2714, middle col., lns.2-8). It is thus unpredictable as to how one might extrapolate particularly dysregulated specific miRNAs from EVs of a urine sample in IPF subjects to the diagnosis or detection of any other type of fibrosis using any other miRNAs form EVs from any other tissue or fluid sample. Quantity of experimentation required A large and prohibitive amount of experimentation would have to be performed in order to make and use the invention in the full scope of the claims. One would have to establish that any compared level of any miRNA from EVs from any fluid or tissue sample from any organism is reliably and robustly associated with any form of fibrosis. . Within the scope of the claims, this would require large case:control studies for the analysis of samples in different organisms, and examining samples from different sources (e.g. blood, tissues, saliva), in an attempt to establish that any level of expression (e.g. any amount of up or down regulation) of miRNA is reliably associated with any fibrosis. Even if such a large amount of experimentation were to be performed, there is no assurance that one would in fact identify a particular combination of relevnat miRNA expression other than the particular method exemplified by the example of the instant specification. Conclusion Taking into consideration the factors outlined above, including the nature of the invention and breadth of the claims, the state of the art, the level of skill in the art and its high level of unpredictability, the provided guidance and the description of the working example, it is the conclusion that an undue amount of experimentation would be required to make and use the invention as claimed. Conclusion No claim is allowed. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. The claims have been examined, consonant with the election of 07/29/2026 and the partial withdrawal of the species election as noted above in this Office Action, as they require: miRNAs in the EVs; and the combination of miRNAs and WNT proteins in the EVs. The claims are not examined in so far as they may be directed to detection of only WNT proteins as a diagnostic for fibrosis. However, in this regard it is noted that Martin-Medina (2018) provides teachings related to the detection of WNT-5A in EVs from bronchoalveolar lavage fluid (BALF) related to the presence of idiopathic pulmonary fibrosis. Any inquiry concerning this communication or earlier communications from the examiner should be directed to STEPHEN THOMAS KAPUSHOC whose telephone number is (571)272-3312. The examiner can normally be reached M-F, 8am-5pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Anne Gussow can be reached at 571-272-6047. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. Stephen Kapushoc Primary Examiner Art Unit 1683 /STEPHEN T KAPUSHOC/Primary Examiner, Art Unit 1683
Read full office action

Prosecution Timeline

Sep 19, 2022
Application Filed
Oct 08, 2026
Non-Final Rejection mailed — §101, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12716097
BIOMARKERS FOR THE DIAGNOSIS OF ATRIAL FIBRILLATION CAUSE OF STROKE
4y 2m to grant Granted Aug 25, 2026
Patent 12704520
MELANOGENESIS DETECTION METHOD USING FAM86A
4y 5m to grant Granted Aug 11, 2026
Patent 12698531
METHODS OF PREDICTING ANEURYSMS OF THE ASCENDING AND DESCENDING AORTA
3y 9m to grant Granted Aug 04, 2026
Patent 12687517
ANALYTE SEQUENCING WITH NANOPORES
2y 6m to grant Granted Jul 21, 2026
Patent 12680135
DIAGNOSTIC ASSAY FOR TISSUE TRANSPLANTATION STATUS
3y 5m to grant Granted Jul 14, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
47%
Grant Probability
99%
With Interview (+53.6%)
3y 9m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 744 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month